未登录

L

Lufang Zhou

The Ohio State University

H指数:33

被引数:2,842

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Combine antibody-drug conjugate with cmLumiOpto for triple-negative breast cancer treatment

将抗体药物偶联物与cmLumiOpto结合用于三阴性乳腺癌治疗

Cell Reports Medicine

IF10.6

2026-07-240

OAAI

Combine mitochondrial-targeted gene therapy and chemotherapy to treat triple-negative breast cancer

结合靶向线粒体的基因治疗和化疗来治疗三阴性乳腺癌

Journal of Experimental & Clinical Cancer Research

IF12.8

2025-12-290

OAAI

Correction: Si et al. Dual-Targeted Extracellular Vesicles to Facilitate Combined Therapies for Neuroendocrine Cancer Treatment. Pharmaceutics 2020, 12, 1079

更正：Si等人. 双靶向外泌体以促进神经内分泌癌症治疗中的联合疗法。Pharmaceutics 2020, 12, 1079

Pharmaceutics 2025, Vol. 17, Page 1317

IF0

2025-10-110

OAAI

Optogenetic mitochondrial preconditioning enhances cardiomyocyte survival under stress

光遗传线粒体预适应增强心肌细胞在应激下的存活率

Journal of Molecular and Cellular Cardiology

IF4.7

2025-06-080

OA

mLumiOpto Is a Mitochondrial-Targeted Gene Therapy for Treating Cancer

CANCER RESEARCH

IF16.6

2024-09-170

OAAI

A Dual-Payload Antibody-Drug Conjugate Targeting CD276/B7-H3 Elicits Cytotoxicity and Immune Activation in Triple-Negative Breast Cancer

CANCER RESEARCH

IF16.6

2024-08-261

OAAI

Pannexin-2 Deficiency Exacerbates Stress-induced Cell Injury in Cardiomyocytes

CIRCULATION RESEARCH

IF16.2

2024-08-020

PRE

Dual payload immunochemotherapy to treat CD276 positive cancers

CANCER RESEARCH

IF16.6

2024-03-220

PRE

Advanced biomanufacturing and evaluation of adeno-associated virus

腺相关病毒的先进生物制造和评估

JOURNAL OF BIOLOGICAL ENGINEERING

IF6.5

2024-02-152

OAAI

Targeted Extracellular Vesicles Delivered Verrucarin A to Treat Glioblastoma. (vol 10 , 130 , 2022)

IF3.9

2023-12-290

OAAI

Characterization of the far-red fluorescent probe MitoView 633 for dynamic mitochondrial membrane potential measurement

FRONTIERS IN PHYSIOLOGY

IF3.4

2023-10-234

OAAI

A CD276-Targeted Antibody-Drug Conjugate to Treat Non-Small Lung Cancer (NSCLC)

一种治疗非小细胞肺癌 (NSCLC) 的CD276-Targeted抗体-药物偶联物

IF5.2

2023-09-301

OAAI

Novel Roles for the Transcriptional Repressor E4BP4 in Both Cardiac Physiology and Pathophysiology

JACC-BASIC TO TRANSLATIONAL SCIENCE

IF7.2

2023-09-016

OA

Activation of Autophagic Flux Maintains Mitochondrial Homeostasis during Cardiac Ischemia/Reperfusion Injury

IF5.2

2022-07-0412

OAAI

Targeted Extracellular Vesicles Delivered Verrucarin A to Treat Glioblastoma

IF3.9

2022-01-0714

OAAI

Targeted EV to Deliver Chemotherapy to Treat Triple-Negative Breast Cancers

IF5.5

2022-01-0713

OAAI

Anti-CD47 Monoclonal Antibody-Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers

Anti-CD47单克隆抗体-药物偶联物: 治疗三阴性乳腺癌的靶向治疗

IF3.4

2021-08-1022

OAAI

Antibody-Drug Conjugate to Treat Meningiomas

PHARMACEUTICALS

IF4.8

2021-05-026

OAAI

Ablation of lncRNA Miat attenuates pathological hypertrophy and heart failure

IF13.3

2021-01-0138

OAAI

Dual-Targeted Extracellular Vesicles to Facilitate Combined Therapies for Neuroendocrine Cancer Treatment

IF5.5

2020-11-1116

OAAI